Benefit of primary and secondary prophylactic implantable cardioverter defibrillator in elderly patients

被引:5
|
作者
Lewenhardt, Marie [1 ]
Kreimer, Fabienne [1 ]
Aweimer, Assem [2 ]
Pflaumbaum, Andreas [1 ]
Muegge, Andreas [1 ]
Gotzmann, Michael [1 ,3 ]
机构
[1] Ruhr Univ, Cardiol & Rhythmol, Univ Hosp St Josef Hosp Bochum, Gudrunstr 56, D-44791 Bochum, Germany
[2] Ruhr Univ, Univ Hosp Bergmannsheil Bochum, Cardiol, Bochum, Germany
[3] Ruhr Univ Bochum, Univ Hosp St Josef Hosp Bochum, Cardiol & Rhythmol, Gudrunstr 56, D-44791 Bochum, Germany
关键词
appropriate ICD therapy; benefit; elderly patients; implantable cardioverter defibrillator; ANTIARRHYTHMIC-DRUG THERAPY; PRIMARY PREVENTION; MANAGEMENT; AGE;
D O I
10.1002/clc.24191
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The benefit of implantable cardioverter-defibrillator (ICD) in elderly patients has been questioned. In the present study, we aimed to analyse the outcome of patients of different age groups with ICD implantation.Methods We included all patients who received an ICD in our hospital from 2011 to 2020. Primary endpoints were (1) death from any cause and (2) appropriate ICD therapy (antitachycardia pacing/shock). A "benefit of ICD implantation" was defined as appropriate ICD therapy before death from any cause/or survival. "No benefit of ICD implantation" was defined as death from any cause without prior appropriate ICD therapy.Results A total of 422 patients received an ICD (primary prophylaxis n = 323, secondary prophylaxis n = 99). At the time of implantation, 35 patients (8%) were >80 years and 106 patients were >75 years (25%). During the study period of 4.2 +/- 3 years, benefit of ICD occurred in 89 patients (21%) and no benefit in 84 patients (20%). In primary prevention, the proportion of patients who had a benefit from ICD implantation decreased with increasing age, and there were no patients who benefited from ICD therapy in the group of patients >80 years. In secondary prophylaxis, the proportion of patients with a benefit from ICD implantation ranged from 20% to 30% in all age groups.Conclusion Our study suggests that the indication of primary prophylactic ICD in elderly and very old patients should be critically assessed. On the other hand, no patient should be denied secondary prophylactic ICD implantation because of age.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Survival after implantation of an implantable cardioverter-defibrillator in elderly patients
    Brilakis, ES
    Valverde, A
    Luria, D
    Cha, YM
    Scott, C
    Rea, R
    Friedman, PA
    Shen, WK
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 108A - 108A
  • [32] Implantable Cardioverter-Defibrillator Implantation, Continuation, and Deactivation in Elderly Patients
    Schleifer J.W.
    Shen W.-K.
    Current Geriatrics Reports, 2017, 6 (4) : 279 - 289
  • [33] Reply to "How to consider the indication of implantable cardioverter defibrillator in the elderly patients"
    Gotzmann, Michael
    Lewenhardt, Marie
    Kreimer, Fabienne
    CLINICAL CARDIOLOGY, 2024, 47 (12)
  • [34] Comparison and predictors of implantable cardioverter-defibrillator therapy for primary and secondary prevention
    Reinder Evertz
    Tessa van der Heijden
    Rypko Beukema
    Sjoerd Westra
    Esther Meindersma
    Caroline van Deursen
    Kevin Vernooy
    Netherlands Heart Journal, 2023, 31 : 348 - 356
  • [35] Clinical relevance of slow ventricular tachycardia in heart failure patients with primary prophylactic implantable cardioverter defibrillator indication
    Luesebrink, Ulrich
    Duncker, David
    Hess, Michaela
    Heinrichs, Irma
    Gardiwal, Ajmal
    Oswald, Hanno
    Koenig, Thorben
    Klein, Gunnar
    EUROPACE, 2013, 15 (06): : 820 - 826
  • [36] Implantable cardioverter-defibrillator implantation for primary and secondary prevention: indications and outcomes
    Pick, Justin M.
    Batra, Anjan S.
    CARDIOLOGY IN THE YOUNG, 2017, 27 : S126 - S131
  • [37] Comparison and predictors of implantable cardioverter-defibrillator therapy for primary and secondary prevention
    Evertz, Reinder
    van der Heijden, Tessa
    Beukema, Rypko
    Westra, Sjoerd
    Meindersma, Esther
    van Deursen, Caroline
    Vernooy, Kevin
    NETHERLANDS HEART JOURNAL, 2023, 31 (09) : 348 - 356
  • [38] Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy - The Canadian implantable defibrillator study
    Sheldon, R
    Connolly, S
    Krahn, A
    Roberts, R
    Gent, M
    Gardner, M
    CIRCULATION, 2000, 101 (14) : 1660 - 1664
  • [39] ATTRIBUTES OF A PROPHYLACTIC IMPLANTABLE CARDIOVERTER DEFIBRILLATOR - HOW CLOSE ARE WE
    HAUSER, RG
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1993, 16 (03): : 582 - 585
  • [40] Early benefit of implantable cardioverter defibrillator therapy in patients waiting for cardiac transplantation
    Lorga, A
    Geelen, P
    Vanderheyden, M
    Malacky, T
    Primo, J
    Goethals, M
    Wellens, F
    Brugada, P
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1998, 21 (09): : 1747 - 1750